Literature DB >> 9055390

Under open lung conditions inverse ratio ventilation causes intrinsic PEEP and hemodynamic impairment.

A M Markström1, M Lichtwarck-Aschoff, A J Hedlund, K A Nordgren, U H Sjöstrand.   

Abstract

Inverse ratio ventilation (IRV) is commonly used in clinical practice. Several studies have used IRV in order to recruit collapsed alveoli. In a randomised trial in twelve surfactant depleted piglets, the lungs were ventilated with sufficient positive end-expiratory pressure (PEEP) to prevent end-expiratory collapse, and the effects of increased inspiration-to-expiration (I:E ratio) were evaluated. Pressure regulated ventilation (with I:E of 1:1, constant tidal volume and decelerating inspiratory flow) was used at 30 breaths per minute (bpm). I:E ratios of 1.5:1, 2.3:1 and 4:1 were applied sequentially. When the I:E ratio was increased, external PEEP had to be reduced in order to keep total PEEP constant. Functional residual capacity, airway pressures, gas exchange, extrathermal volume and hemodynamics were measured. With I:E ratios above 2:1 intrinsic PEEP was generated and with concomitant decrease in cardiac index. PaO2 was not affected, but oxygen delivery was reduced. It is concluded that I:E ratios of 2:1, or above, generate increased intrinsic PEEP with compromised hemodynamics.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9055390     DOI: 10.3109/03009739609178925

Source DB:  PubMed          Journal:  Ups J Med Sci        ISSN: 0300-9734            Impact factor:   2.384


  2 in total

1.  Effects of inverse ratio ventilation combined with lung protective ventilation on pulmonary function in patients with severe burns for surgery.

Authors:  Yan-Chao Yang; Qiao Huai; Shu-Zhen Cui; Xiao-Wei Cao; Bu-Lang Gao
Journal:  Libyan J Med       Date:  2020-12       Impact factor: 1.657

2.  Lung-protective properties of expiratory flow-initiated pressure-controlled inverse ratio ventilation: A randomised controlled trial.

Authors:  Go Hirabayashi; Minami Saito; Sachiko Terayama; Yuki Akihisa; Koichi Maruyama; Tomio Andoh
Journal:  PLoS One       Date:  2020-12-17       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.